Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 5 recruiting now early-phase tilt small index

Hematologic Cancer: early-phase trial registry

5 of 5 indexed Hematologic Cancer trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #3,391 of 28,707 conditions by registered trial count.

5 US clinical trials · 5 currently recruiting · #3,391 of 28,707 conditions by registered trial count

Hematologic Cancer: 5 US clinical trials tracked, 5 recruiting.

Hematologic Cancer is the subject of 5 registered US clinical trials on ClinicalTrials.gov, 5 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Nadine McCleary, MD, MPH, running 1 of these trials.

Enrollment posture brief

Registry condition hematologic-cancer

OPEN 5 | RECR 100% | LATE 0 | EARLY 1 | RANK #3391 | SPON 1

Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)

Hematologic Cancer (this)100%Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%
Open-enrollment share among volume-matched conditions near Hematologic Cancer

Hematologic Cancer lists 5 open slots (100% of 5 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Hematologic Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Hematologic Cancer is recruiting above its size-band peers.

    5 of 5 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Hematologic Cancer research.

    Nadine McCleary, MD, MPH accounts for 1 of 5 trials (20%). 5 distinct sponsors appear on at least one study for this condition label.

  3. Typical Hematologic Cancer enrolment sits around 210 participants.

    Median target enrolment is 210 among the 5 trials that report a genuine target (sentinel values excluded). 1 of those (20%) plan for fewer than 100 participants.

  4. Hematologic Cancer research is mostly interventional.

    5 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 11

Phase Distribution

PhaseTrial count
Phase 1 1

Named interventions

Most-linked intervention names on Hematologic Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

CBT for Fatigue Behavioral
1 trials
MyCarePulse and ASCENT PN Behavioral
1 trials
SURGE Behavioral
1 trials
ABBV-101 Drug
1 trials
OPTIMISE Behavioral
1 trials
Usual Care Behavioral
1 trials

US sites by state

Facility locations filed on Hematologic Cancer trials. A trial with sites in several states counts in each.

Massachusetts 3 trials
Texas 2 trials
Pennsylvania 1 trials
Oregon 1 trials
Ohio 1 trials
New York 1 trials
New Jersey 1 trials
Illinois 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Hematologic Cancer page

5 registered trials, 5 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Hematologic Cancer condition card totals 5 registered trials; most-linked intervention CBT for Fatigue; top US site state Massachusetts. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.